Axsome Therapeutics, Inc. has grown revenue 62% a year over three years and 134% a year over five. Revenue growth, 3-year annual rate: +62% (Biotechnology median +17%). Revenue growth, 5-year rate: +134%, growth has slowed since the five-year average. Years of annual history on file: 12, FY2014 to FY2025, as filed.

AXSMAxsome Therapeutics, Inc.

Healthcare

$168.44+45% 1Y

$168.44

$116.0152 weeks$255.17

Is it growing?

Good

Growing: revenue growing +57% year on year and operating margin widening (+23.9 points).

2 good, 1 without data

Revenue trend+57% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings.

Margin direction+23.9 points operating

Trailing-twelve-month operating margin, -24.1% now against -48.1% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is AXSM growing?

Axsome Therapeutics, Inc. has grown revenue 62% a year over three years and 134% a year over five.

+62%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +134%
Revenue growth, 5-year rate · +62% over three · growth has slowed since the five-year average
Years of annual history on file: 12
Years of annual history on file · FY2014 to FY2025, as filed

Details›